Zhang Y, Chen Z, Li J (2017) The current status of treatment for colorectal cancer in China: a systematic review. Med (Baltim) 96:e8242. https://doi.org/10.1097/md.0000000000008242

Article  Google Scholar 

Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7–30. https://doi.org/10.3322/caac.21442

Article  PubMed  Google Scholar 

Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB (2019) Colorectal cancer. Lancet (London England) 394(10207):1467–1480. https://doi.org/10.1016/S0140-6736(19)32319-0

Article  PubMed  Google Scholar 

Weng ML, Chen WK, Chen XY, Lu H, Sun ZR, Yu Q, Sun PF, Xu YJ, Zhu MM, Jiang N, Zhang J, Zhang JP, Song YL, Ma D, Zhang XP, Miao CH (2020) Fasting inhibits aerobic glycolysis and proliferation in colorectal cancer via the Fdft1-mediated AKT/mTOR/HIF1α pathway suppression. Nat Commun 11(1):1869. https://doi.org/10.1038/s41467-020-15795-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tewari D, Patni P, Bishayee A, Sah AN, Bishayee A (2022) Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: a novel therapeutic strategy. Semin Cancer Biol 80:1–17. https://doi.org/10.1016/j.semcancer.2019.12.008

Article  PubMed  Google Scholar 

Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124:471–484. https://doi.org/10.1016/j.cell.2006.01.016

Article  CAS  PubMed  Google Scholar 

Wang H, Liu Y, Ding J, Huang Y, Liu J, Liu N, Ao Y, Hong Y, Wang L, Zhang L, Wang J, Zhang Y (2020) Targeting mTOR suppressed colon cancer growth through 4EBP1/eIF4E/PUMA pathway. Cancer Gene Ther 27:448–460. https://doi.org/10.1038/s41417-019-0117-7

Article  CAS  PubMed  Google Scholar 

Deleyto-Seldas N, Efeyan A (2021) The mTOR-Autophagy Axis and the control of metabolism. Front Cell Dev Biol 9:655731. https://doi.org/10.3389/fcell.2021.655731

Article  PubMed  PubMed Central  Google Scholar 

Saxton RA, Sabatini DM (2017) mTOR Signaling in Growth, Metabolism, and Disease. Cell 169:361–371. https://doi.org/10.1016/j.cell.2017.03.035

Article  CAS  PubMed  Google Scholar 

Hua H, Kong Q, Zhang H, Wang J, Luo T, Jiang Y (2019) Targeting mTOR for cancer therapy. J Hematol Oncol 12:71. https://doi.org/10.1186/s13045-019-0754-1

Article  PubMed  PubMed Central  Google Scholar 

Yin Y, Hua H, Li M, Liu S, Kong Q, Shao T, Wang J, Luo Y, Wang Q, Luo T, Jiang Y (2016) mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR. Cell Res 26:46–65. https://doi.org/10.1038/cr.2015.133

Article  CAS  PubMed  Google Scholar 

Vergès B, Walter T, Cariou B (2014) Endocrine side effects of anti-cancer drugs: effects of anti-cancer targeted therapies on lipid and glucose metabolism. Eur J Endocrinol 170:R43–55. https://doi.org/10.1530/eje-13-0586

Article  PubMed  Google Scholar 

Szwed A, Kim E, Jacinto E (2021) Regulation and metabolic functions of mTORC1 and mTORC2. Physiol Rev 101(3):1371–1426. https://doi.org/10.1152/physrev.00026.2020

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim LC, Cook RS, Chen J (2017) mTORC1 and mTORC2 in cancer and the tumor microenvironment. Oncogene 36(16):2191–2201. https://doi.org/10.1038/onc.2016.363

Article  CAS  PubMed  Google Scholar 

Carew JS, Kelly KR, Nawrocki ST (2011) Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol 6:17–27. https://doi.org/10.1007/s11523-011-0167-8

Article  PubMed  Google Scholar 

Lou J, Lv JX, Zhang YP, Liu ZJ (2022) OSI-027 inhibits the tumorigenesis of colon cancer through mediation of c-Myc/FOXO3a/PUMA axis. Cell Biol Int 46(8):1204–1214. https://doi.org/10.1002/cbin.11792

Article  CAS  PubMed  Google Scholar 

Bhagwat SV, Gokhale PC, Crew AP, Cooke A, Yao Y, Mantis C, Kahler J, Workman J, Bittner M, Dudkin L, Epstein DM, Gibson NW, Wild R, Arnold LD, Houghton PJ, Pachter JA (2011) Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther 10(8):1394–1406. https://doi.org/10.1158/1535-7163.MCT-10-1099

Article  CAS  PubMed  Google Scholar 

Afzal O, Altamimi ASA, Mubeen B, Alzarea SI, Almalki WH, Al-Qahtani SD, Atiya EM, Al-Abbasi FA, Ali F, Ullah I, Nadeem MS, Kazmi I (2022) mTOR as a potential target for the Treatment of Microbial Infections, Inflammatory Bowel diseases, and Colorectal Cancer. Int J Mol Sci 23(20):12470. https://doi.org/10.3390/ijms232012470

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vander Heiden MG, DeBerardinis RJ (2017) Understanding the intersections between Metabolism and Cancer Biology. Cell 168:657–669. https://doi.org/10.1016/j.cell.2016.12.039

Article  CAS  PubMed  Google Scholar 

Zhang Y, Kwok-Shing Ng P, Kucherlapati M, Chen F, Liu Y, Tsang YH, de Velasco G, Jeong KJ, Akbani R, Hadjipanayis A, Pantazi A, Bristow CA, Lee E, Mahadeshwar HS, Tang J, Zhang J, Yang L, Seth S, Lee S, Ren X, Song X, Sun H, Seidman J, Luquette LJ, Xi R, Chin L, Protopopov A, Westbrook TF, Shelley CS, Choueiri TK, Ittmann M, Van Waes C, Weinstein JN, Liang H, Henske EP, Godwin AK, Park PJ, Kucherlapati R, Scott KL, Mills GB, Kwiatkowski DJ, Creighton CJ (2017) A Pan-cancer Proteogenomic Atlas of PI3K/AKT/mTOR pathway alterations. Cancer Cell 31:820–832e823. https://doi.org/10.1016/j.ccell.2017.04.013

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ganley IG, Lam duH, Wang J, Ding X, Chen S, Jiang X (2009) ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy. J Biol Chem 284(18):12297–12305. https://doi.org/10.1074/jbc.M900573200

Article  CAS  PubMed  PubMed Central  Google Scholar 

Massari F, Ciccarese C, Santoni M, Iacovelli R, Mazzucchelli R, Piva F, Scarpelli M, Berardi R, Tortora G, Lopez-Beltran A, Cheng L, Montironi R (2016) Metabolic phenotype of bladder cancer. Cancer Treat Rev 45:46–57. https://doi.org/10.1016/j.ctrv.2016.03.005

Article  CAS  PubMed  Google Scholar 

Schmidt S, Denk S, Wiegering A (2020) Targeting protein synthesis in Colorectal Cancer. Cancers 12(5):1298. https://doi.org/10.3390/cancers12051298

Article  CAS  PubMed  PubMed Central  Google Scholar 

DeBerardinis RJ, Chandel NS (2016) Fundamentals of cancer metabolism. Sci Adv 2:e1600200. https://doi.org/10.1126/sciadv.1600200

Article  CAS  PubMed  PubMed Central  Google Scholar 

Levine AJ, Puzio-Kuter AM (2010) The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330:1340–1344. https://doi.org/10.1126/science.1193494

Article  CAS  PubMed  Google Scholar 

Chakraborty S, Balan M, Sabarwal A, Choueiri TK, Pal S (2021) Metabolic reprogramming in renal cancer: events of a metabolic disease. Biochim Biophys Acta Rev Cancer 1876:188559. https://doi.org/10.1016/j.bbcan.2021.188559

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pavlova NN, Zhu J, Thompson CB (2022) The hallmarks of cancer metabolism: still emerging. Cell Metab 34:355–377. https://doi.org/10.1016/j.cmet.2022.01.007

Article  CAS